{
    "name": "mesalamine rectal",
    "comment": "Rx",
    "other_names": [
        "Canasa",
        "Rowasa"
    ],
    "classes": [
        "5-Aminosalicylic Acid Derivatives"
    ],
    "source": "https://reference.medscape.com/drug/canasa-rowasa-mesalamine-rectal-999555",
    "pregnancy": {
        "common": [
            "Limited published data on mesalamine use in pregnant women are insufficient to inform a drug-associated risk"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "No evidence of teratogenicity was observed in rats or rabbits when treated during gestation with orally administered mesalamine at doses greater than the recommended human intra-rectal dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Mesalamine and its N-acetyl metabolite are present in human milk in undetectable to small amounts; there are limited reports of diarrhea in breastfed infants; there is no information on effects of drug on milk production",
            "The lack of clinical data during lactation precludes a clear determination of the risk to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed child from the drug or from underlying maternal conditions"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to mesalamine, excipients, salicylates, or aminosalicylates"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in patients with coagulation abnormalities, pyloric stenosis",
                "Rare instances of pericarditis reported with mesalamine containing products; investigate any chest pain or dyspnea",
                "Acute intolerance syndrome characterized by cramping, acute abdominal pain, bloody diarrhea, sometimes fever, headache, and a rash; monitor patients for worsening of these symptoms while on treatment; if acute intolerance syndrome suspected, promptly discontinue treatment",
                "Follow instruction for use for rectal suppository and enema",
                "For maximum benefit, retain rectal suppository for 1-3 hr; retain rectal suspension for 8 hr",
                "Hepatic failure may occur, particularly with pre-existing liver disease who have been administered other products containing mesalamine; evaluate risks and benefits of using this product in patients with known liver impairment",
                "May lead to falsely elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection, because of the similarity in the chromatograms of normetanephrine and mesalamine’s main metabolite, N-acetyl aminosalicylic acid",
                "Consider monitoring complete blood cell counts and platelet counts in elderly patients during treatment, especially if used concomitantly with anticoagulants; in general, consider greater frequency of decreased hepatic, renal, or cardiac function, and of concurrent disease or other drug therapy in elderly patients when prescribing therapy",
                "Cases of nephrolithiasis reported with use of mesalamine, including stones of 100% mesalamine content; mesalamine-containing stones are radiotransparent and undetectable by standard radiography or computed tomography (CT); ensure adequate hydration during treatment",
                "Patients treated with mesalamine or sulfasalazine with pre-existing skin conditions such as atopic dermatitis and atopic eczema may experience more severe photosensitivity reactions; advise patients to avoid sun exposure, wear protective clothing, and use a broad-spectrum sunscreen when outdoors"
            ],
            "specific": [
                {
                    "type": "Renal impairment",
                    "description": [
                        "Renal impairment, including minimal change disease, acute, and chronic interstitial nephritis, and renal failure, reported in patients given products that contain mesalamine or are converted to mesalamine; in animal studies, the kidney was the principal organ of mesalamine toxicity",
                        "Evaluate renal function prior to initiation of therapy and periodically while on therapy; evaluate risks and benefits of using this drug in patients with known renal impairment or a history of renal disease or taking concomitant nephrotoxic drugs"
                    ]
                },
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "Hypersensitivity reported in patients taking sulfasalazine; some patients may have a similar reaction to this product or to other compounds that contain or are converted to mesalamine",
                        "As with sulfasalazine, mesalamine-induced hypersensitivity reactions may present as internal organ involvement, including myocarditis, pericarditis, nephritis, hepatitis, pneumonitis, and hematologic abnormalities",
                        "Evaluate patients immediately if signs or symptoms of a hypersensitivity reaction are present; discontinue this product if an alternative etiology for signs and symptoms cannot be established"
                    ]
                },
                {
                    "type": "Severe Cutaneous Adverse Reactions",
                    "description": [
                        "Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) reported in association with use of this drug",
                        "Discontinue therapy at first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Dizziness",
            "percent": "3"
        },
        {
            "name": "Rectal pain",
            "percent": "1.8"
        },
        {
            "name": "Fever",
            "percent": "1.2"
        },
        {
            "name": "Rash",
            "percent": "1.2"
        },
        {
            "name": "Acne",
            "percent": "1.2"
        },
        {
            "name": "Colitis",
            "percent": "1.2"
        }
    ]
}